This site contains promotional information intended only for healthcare professionals resident in the United Kingdom
Sign in
Sign In or Register
Sign out

Information relating to specific disease areas aligned to Pfizer’s portfolio and other resources designed for Pfizer medicines.

See all Therapy areas

Explore Content

The content of this website has been produced in line with the BESPONSA®▼ (inotuzumab ozogamicin) Summary of Product Characteristics for Great Britain and is intended for Healthcare Professionals based in Great Britain. BESPONSA▼ Prescribing Information for Great Britain click here. BESPONSA▼ Prescribing Information for Northern Ireland click here. Adverse event reporting information can be found at the bottom of the page.

Hospitalisation Data

Aim for reduced hospitalisation time1

In a retrospective analysis of the long term data from INO-VATE study; of the patients who received at least one dose of study drug (BESPONSA n=164 vs SC n=143), BESPONSA reduced hospitalisation times when compared with standard chemotherapy

Hospitalisation for both groups was mainly for treatment of underlying disease and toxicity including haematological toxicity and infection1

Overall, 136 of 164 (82.9%) BESPONSA patients and 135 of 143 (94.4%) SC patients experienced at least one hospitalisation1.
BESPONSA patients were observed for a mean of 85.0 days vs 45.2 for SC up to a total of 13,946 vs 6463 days, respectively1.

*Treatment of underlying disease includes hospitalisations for scheduled treatment related to ALL or study participation, relapse and preparation for HSCT.
ALL, acute lymphoblastic leukaemia; HSCT, haematopoietic stem cell transplantation; IRR, incidence rate ratio; SC, standard chemotherapy.

Explore more

Developments in Leukaemia Care video

Watch Professor David Marks discuss targeted therapies and the INO-VATE study, including 3 year follow up and impact of allogeneic bone marrow transplantation on survival

Learn More

Management of Refractory/Relapsed ALL video

Hear Professor David Marks discuss the INO-VATE study including MRD negativity, long term survival and reducing risks of veno-occlusive disease

Learn More

 This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. See section 4.8 of the SmPC for how to report adverse reactions.
  1. Marks DI, et al. Cancer Med 2019; 5959-5968
PP-INO-GBR-0623. February 2022

Quick Links

Fast Facts

Download the Fast Facts Guide holding the key information for BESPONSA including mode of action, INO-VATE study design, INO-VATE results; efficacy and safety profile

Download here

For UK Healthcare Professionals*

These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.

I confirm that I am a healthcare professional* resident in the United Kingdom.

If you select 'No', you will be redirected to where you will be able to access reference information on Pfizer's prescription medicines.

*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.

PP-PFE-GBR-3863. November 2021



OK, We will need you to sign in before we can determine if you are aligned with a Pfizer promotional colleague.This is an interstitial message to prompt a HCP before they login.

If you have already registered with and select ‘yes’, you will be directed to the sign-in page where you will be required to enter your username and password.

Would you like to register or sign in now?